Patent ID: 8795725
Filing Date: 2014-08-05
Classification: A61K,A61P

Abstract:
1. A sustained release oral tablet comprising: (a) 40 wt % to 65 wt % of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid; (b) 1 wt % to 30 wt % of glyceryl behenate; and (c) 30 wt % to 50 wt % of dibasic calcium phosphate; wherein wt % is based on the total dry weight of the dosage form, which tablet: when administered to one or more fasted human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a C when administered to one or more fed human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a C